Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

詳細情報 詳細情報について

• CRID

  1361981470492190720

• DOI

  10.1016/s1470-2045(15)00006-6

• ISSN

  14702045

• Web Site

  https://api.elsevier.com/content/article/PII:S1470204515000066?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S1470204515000066?httpAccept=text/plain

• データソース種別

  • Crossref